Richard J. Willke

6.4k total citations · 3 hit papers
83 papers, 4.5k citations indexed

About

Richard J. Willke is a scholar working on Economics and Econometrics, General Health Professions and Statistics and Probability. According to data from OpenAlex, Richard J. Willke has authored 83 papers receiving a total of 4.5k indexed citations (citations by other indexed papers that have themselves been cited), including 54 papers in Economics and Econometrics, 20 papers in General Health Professions and 14 papers in Statistics and Probability. Recurrent topics in Richard J. Willke's work include Health Systems, Economic Evaluations, Quality of Life (51 papers), Healthcare Policy and Management (17 papers) and Healthcare cost, quality, practices (16 papers). Richard J. Willke is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (51 papers), Healthcare Policy and Management (17 papers) and Healthcare cost, quality, practices (16 papers). Richard J. Willke collaborates with scholars based in United States, United Kingdom and Netherlands. Richard J. Willke's co-authors include Henry A. Glick, Kevin A. Schulman, Shelby D. Reed, Andrew Briggs, Louis P. Garrison, Peter J. Neumann, Daniel Polsky, Scott D. Ramsey, Pennifer Erickson and Laurie B. Burke and has published in prestigious journals such as Circulation, Cancer and Stroke.

In The Last Decade

Richard J. Willke

83 papers receiving 4.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Good Research Practices for Cost-Effectiveness Analysis Alongside Clinical Trials: The ISPOR RCT-CEA Task Force Report

2005 532 citations Richard J. Willke, Henry A. Glick et al. Value in Health profile →
Cost-Effectiveness Analysis Alongside Clinical Trials II—An ISPOR Good Research Practices Task Force Report

2015 498 citations Scott D. Ramsey, Richard J. Willke et al. Value in Health profile →
Good Practices for Real‐World Data Studies of Treatment and/or Comparative Effectiveness: Recommendations from the Joint ISPOR‐ISPE Special Task Force on Real‐World Evidence in Health Care Decision Making

2017 327 citations Marc L. Berger, Harold C. Sox et al. Value in Health profile →

Peers

Countries citing papers authored by Richard J. Willke

Since Specialization

Citations

This map shows the geographic impact of Richard J. Willke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard J. Willke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard J. Willke more than expected).

Fields of papers citing papers by Richard J. Willke

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard J. Willke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard J. Willke. The network helps show where Richard J. Willke may publish in the future.

Co-authorship network of co-authors of Richard J. Willke

This figure shows the co-authorship network connecting the top 25 collaborators of Richard J. Willke. A scholar is included among the top collaborators of Richard J. Willke based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard J. Willke. Richard J. Willke is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Comparative effectiveness and safety of pharmaceuticals assessed in observational studies compared with randomized controlled trials 2021 ·BMC Medicine ·(unknown), Jeroen P. Jansen, (unknown), Marc L. Berger, William H. Crown, Wim Goettsch, C. Daniel Mullins, Richard J. Willke, Lucinda Orsini	13
2	Criteria and Process for Initiating and Developing an ISPOR Good Practices Task Force Report 2020 ·Value in Health ·Daniel C. Malone, Scott D. Ramsey, Donald L. Patrick, F. Reed Johnson, C. Daniel Mullins, Mark S. Roberts, Richard J. Willke, Deborah A. Marshall	20
3	New Approaches to Value Assessment: Towards More Informed Pricing in Healthcare—An Introduction 2019 ·Value in Health ·Richard J. Willke	3
4	A Health Economics Approach to US Value Assessment Frameworks—Summary and Recommendations of the ISPOR Special Task Force Report [7] 2018 ·Value in Health ·Louis P. Garrison, Peter J. Neumann, Richard J. Willke, Anirban Basu, Patricia M. Danzon, Jalpa A. Doshi, Michael Drummond, Darius Lakdawalla, Mark V. Pauly, Charles E. Phelps, Scott D. Ramsey, Adrian Towse, Milton C. Weinstein	110
5	Review of Recent US Value Frameworks—A Health Economics Approach: An ISPOR Special Task Force Report [6] 2018 ·Value in Health ·Richard J. Willke, Peter J. Neumann, Louis P. Garrison, Scott D. Ramsey	46
6	A Health Economics Approach to US Value Assessment Frameworks—Introduction: An ISPOR Special Task Force Report [1] 2018 ·Value in Health ·Peter J. Neumann, Richard J. Willke, Louis P. Garrison	98
7	Good Practices for Real‐World Data Studies of Treatment and/or Comparative Effectiveness: Recommendations from the Joint ISPOR‐ISPE Special Task Force on Real‐World Evidence in Health Care Decision Making breakdown → 2017 ·Value in Health ·Marc L. Berger, Harold C. Sox, Richard J. Willke, Diana Brixner, Hans‐Georg Eichler, Wim Goettsch, David Madigan, Amr Makady, Sebastian Schneeweiß, Rosanna Tarricone, Shirley Wang, John B. Watkins, C. Daniel Mullins	327
8	ISPOR Code of Ethics 2017 (4th Edition) 2017 ·Value in Health ·(unknown), Francis B. Palumbo, (unknown), Richard J. Willke, (unknown), Michael Drummond, Anita Ho, William D. Marder, (unknown), (unknown), Asrul Akmal Shafie, (unknown)	12
9	Melding Regulatory, Pharmaceutical Industry, and U.S. Payer Perspectives on Improving Approaches to Heterogeneity of Treatment Effect in Research and Practice 2013 ·Value in Health ·Richard J. Willke, William H. Crown, Michael del Aguila, Mark J. Cziraky, Zeba M. Khan, Richard J. Migliori	5
10	Treatment Dynamics of Newly Marketed Drugs and Implications for Comparative Effectiveness Research 2013 ·Value in Health ·Joshua J. Gagne, Katsiaryna Bykov, Richard J. Willke, Kristijan H. Kahler, Prasun Subedi, Sebastian Schneeweiß	27
11	Statistical Issues with the Analysis of Nonrandomized Studies in Comparative Effectiveness Research 2011 ·Journal of Managed Care Pharmacy ·Demissie Alemayehu, Jose Ma. J. Alvir, Byron Jones, Richard J. Willke	19
12	Cost Effectiveness of Eplerenone in Patients with Heart Failure after Acute Myocardial Infarction Who were Taking Both ACE Inhibitors and β-Blockers 2010 ·American Journal of Cardiovascular Drugs ·Zefeng Zhang, Elizabeth M. Mahoney, Paul Kolm, John A. Spertus, J. Jaime, Richard J. Willke, William S. Weintraub	16
13	Variability of Cost-Effectiveness Estimates for Pharmaceuticals in Western Europe: Lessons for Inferring Generalizability 2005 ·Value in Health ·Marco Barbieri, Michael Drummond, Richard J. Willke, J Chancellor, (unknown), Adrian Towse	97
14	Effects of linezolid on hospital length of stay compared with vancomycin in treatment of methicillin-resistant Staphylococcus infections. An application of multivariate survival analysis. 2002 ·PubMed ·Richard J. Willke, Henry A. Glick, Jim Z. Li, B Rittenhouse	21
15	Regulatory Issues for Health-Related Quality of Life— PhRMA Health Outcomes Committee Workshop, 1999 2002 ·Value in Health ·Nancy C. Santanello, (unknown), Joseph C. Cappelleri, Catherine Copley‐Merriman, (unknown), Jean Paul Gagnon, (unknown), Jeanne Jackson, Ramy Mahmoud, David W. Miller, Michael K. Morgan, Jane T. Osterhaus, Hugh H. Tilson, Richard J. Willke	25
16	Comparison of Length of Hospital Stay for Patients with Known or Suspected Methicillin‐Resistant Staphylococcus Species Infections Treated with Linezolid or Vancomycin: A Randomized, Multicenter Trial 2001 ·Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy ·Zhiming Li, Richard J. Willke, Lionel Pinto, B Rittenhouse, Michael J. Rybak, Andreas M. Pleil, (unknown), Barry Hafkin, Henry A. Glick	114
17	A comparison of scoring weights for the EuroQol� derived from patients and the general public 2001 ·Health Economics ·Daniel Polsky, Richard J. Willke, (unknown), Kevin A. Schulman, (unknown)	49
18	Relationship Between CD4 Count, Viral Burden, and Quality of Life Over Time in HIV-1-Infected Patients 2000 ·Medical Care ·Kevin P. Weinfurt, Richard J. Willke, (unknown), William W. Freimuth, (unknown)	86
19	Confidence Intervals for Cost-Effectiveness Ratios: A Comparison of Four Methods 1997 ·Health Economics ·Daniel Polsky, Henry A. Glick, Richard J. Willke, Kevin A. Schulman	225
20	Construction of scales for the Center for Marital and Sexual Health (CMASH) sexual functioning questionnaire 1997 ·Journal of Sex & Marital Therapy ·Henry A. Glick, (unknown), Stanley E. Althof, Eric Corty, Richard J. Willke	21

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact